Free Trial

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America

KalVista Pharmaceuticals logo with Medical background

Bank of America started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV - Free Report) in a report published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $22.00 price target on the specialty pharmaceutical company's stock.

A number of other research analysts also recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th.

Read Our Latest Analysis on KalVista Pharmaceuticals

KalVista Pharmaceuticals Stock Down 2.2 %

KALV traded down $0.19 during trading on Wednesday, hitting $8.46. The company had a trading volume of 770,962 shares, compared to its average volume of 476,998. The firm's 50-day moving average price is $10.49 and its 200 day moving average price is $11.69. The company has a market capitalization of $418.08 million, a PE ratio of -2.32 and a beta of 0.85. KalVista Pharmaceuticals has a one year low of $8.25 and a one year high of $16.88.

Insider Activity

In other news, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares of the company's stock, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company's stock, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock valued at $304,086 in the last quarter. Company insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. HighVista Strategies LLC boosted its holdings in shares of KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company's stock worth $386,000 after acquiring an additional 1,432 shares during the period. ClariVest Asset Management LLC grew its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company's stock valued at $673,000 after buying an additional 1,535 shares in the last quarter. Nicholas Investment Partners LP increased its position in KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company's stock worth $2,172,000 after buying an additional 1,714 shares during the period. nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $25,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company's stock valued at $182,000 after acquiring an additional 3,314 shares during the period.

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Featured Stories

Should you invest $1,000 in KalVista Pharmaceuticals right now?

Before you consider KalVista Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.

While KalVista Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines